Multiple Sclerosis (MS) Drug Market

RECENT NEWS
GenEng News  May 27  Comment 
Investigators led by scientists at The Scripps Research Institute (TSRI) say they have invented a technique for rapidly identifying various venoms that strike a specific target in the body and then optimizing such venoms for therapeutic...
Forbes  May 17  Comment 
She drew the life-saving medication into the syringe, just 10cc of colorless fluid for the everyday low price of, gulp, several hundred dollars. Was that a new chemotherapy, specially designed for her tumor? Was it a “specialty drug,” to treat...
Motley Fool  May 8  Comment 
If approved, Ocrevus' combination of safety and efficacy will make it a multiple sclerosis game changer
The Hindu Business Line  May 4  Comment 
Yoga and aquatic exercise may reduce certain symptoms of multiple sclerosis (MS) such as fatigue, depression and paresthesia, a new study suggests. MS is a chronic progressive auto-immune disease i...
Mondo Visione  Apr 15  Comment 
Euronext today celebrated the listing of GeNeuro, a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis, in Compartment B of its regulated market in Paris. Founded in 2006, GeNeuro has...
GenEng News  Apr 11  Comment 
Scientists report that the Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis (MS). The investigators will discuss the results of their research at the upcoming American Academy...
FierceBiotech  Apr 8  Comment 
MedDay has raised $38.5 million in a Series B funding round as it looks toward finishing up late-stage trials for its lead multiple sclerosis candidate--which the company is touting as a "breakthrough drug."
FiercePharma  Mar 7  Comment 
The multiple sclerosis market is a work in progress, with several candidate drugs poised to shake things up and a reimbursement landscape that's growing increasingly tricky. And according to one analyst, that means trouble for Biogen.




 
TOP CONTRIBUTORS

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki